Top Markets
Coin of the day
Aardvark Therapeutics, Inc. Common Stock Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc. Common Stock

AARD
주식 순위 #19553
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical... Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
주가
$7.22
마지막 동기화: 2026-08-25
시가총액
$158.03M
변동 (1일)
4.96%
변동 (1년)
-24.22%
국가
US
거래 Aardvark Therapeutics, Inc. Common Stock (AARD)

카테고리

Aardvark Therapeutics, Inc. Common Stock (AARD)의 배당 수익률 기록
Aardvark Therapeutics, Inc. Common Stock (주식 심볼: AARD)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
Aardvark Therapeutics, Inc. Common Stock (AARD)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 수익률 (TTM)
회사 배당 수익률 국가
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH